Biomarker discovery in asthma and COPD: Application of proteomics techniques in human and mice

EuPA Open Proteomics

Volumn 4, Issue , 2014, Pages 101-112

  Haenen, Steven ^a   Clynen, Elke ^b   Nemery, Benoit ^a   Hoet, Peter H M ^a   Vanoirbeek, Jeroen A J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Animal models; Asthma; COPD; Human; Proteomics

Indexed keywords

ALPHA ENOLASE; ALPHA SMOOTH MUSCLE ACTIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CALCYCLIN; CALGRANULIN A; CALGRANULIN B; DEXAMETHASONE; ENDOTOXIN; FETUIN A; FETUIN B; FIBRINOGEN; GELATINASE B; GELSOLIN; GLUTATHIONE PEROXIDASE 1; HAPTOGLOBIN; HEMOPEXIN; KHELLIN; PEROXIREDOXIN 5; PEROXIREDOXIN 6; PHOSPHODIESTERASE IV; PLASMINOGEN; SALBUTAMOL; SURFACTANT PROTEIN A; THIOREDOXIN; THIOREDOXIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNINDEXED DRUG; VINCULIN; VITAMIN D BINDING PROTEIN;

ALLERGIC ASTHMA; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; HISTOPATHOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; LUNG LAVAGE; MASS SPECTROMETRY; NONHUMAN; OCCUPATIONAL ASTHMA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SPUTUM ANALYSIS; STAINING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 84907275775     PISSN: None     EISSN: 22129685     Source Type: Journal    
DOI: 10.1016/j.euprot.2014.04.008     Document Type: Review

References (98)

1. Ahram M., Petricoin E.F. Proteomics discovery of disease biomarkers. Biomark Insights 2008, 3:325-333.
2. Bogaerts A., Temmerman L., Boerjan B., Husson S.J., Schoofs L., Verleyen P. A differential proteomics study of Caenorhabditis elegans infected with Aeromonas hydrophila. Dev Comp Immunol 2010, 34(6):690-698.
3. Griffith O.L., Gray J.W. Omic approaches to preventing or managing metastatic breast cancer. Breast Cancer Res 2011, 13(6):230.
4. Sun C., Rosendahl A.H., Ansari D., Andersson R. Proteome-based biomarkers in pancreatic cancer. World J Gastroenterol 2011, 17(44):4845-4852.
5. Goh W.W., Lee Y.H., Chung M., Wong L. How advancement in biological network analysis methods empowers proteomics. Proteomics 2012, 12(4-5):550-563.
6. Decramer M., Janssens W., Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012, 379(9823):1341-1351.
7. Cottini M., Asero R. Asthma phenotypes today. Eur Ann Allergy Clin Immunol 2013, 45(1):17-24.
8. Martinez F.D., Vercelli D. Asthma. Lancet 2013, 382(9901):1360-1372.
9. Vahakangas K. Research ethics in the post-genomic era. Environ Mol Mutagen 2013, 54(7):599-610.
10. Hirsch J., Hansen K.C., Burlingame A.L., Matthay M.A. Proteomics: current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol 2004, 287(1):L1-L23.
11. Hackam D.G., Redelmeier D.A. Translation of research evidence from animals to humans. J Am Med Assoc 2006, 296(14):1731-1732.
12. Maddox L., Schwartz D.A. The pathophysiology of asthma. Annu Rev Med 2002, 53:477-498.
13. Busse W.W., Rosenwasser L.J. Mechanisms of asthma. J Allergy Clin Immunol 2003, 111:799-804.
14. Lemanske R.F., Busse W.W. 6. Asthma. J Allergy Clin Immunol 2003, 111(2 Suppl.):S502-S519.
15. Svanes C., Sunyer J., Plana E., Dharmage S., Heinrich J., Jarvis D., et al. Early life origins of chronic obstructive pulmonary disease. Thorax 2010, 65(1):14-20.
16. Lin J.L., Bonnichsen M.H., Nogeh E.U., Raftery M.J., Thomas P.S. Proteomics in detection and monitoring of asthma and smoking-related lung diseases. Expert Rev Proteomics 2010, 7(3):361-372.
17. Wolthers O.D. Eosinophil granule proteins in the assessment of airway inflammation in pediatric bronchial asthma. Pediatr Allergy Immunol 2003, 14(4):248-254.
18. Hopkins A.L., Groom C.R. The druggable genome. Nat Rev Drug Discov 2002, 1(9):727-730.
19. Signor L., Tigani B., Beckmann N., Falchetto R., Stoeckli M. Two-dimensional electrophoresis protein profiling and identification in rat bronchoalveolar lavage fluid following allergen and endotoxin challenge. Proteomics 2004, 4(7):2101-2110.
20. Haenen S., Vanoirbeek J.A., De Vooght V., Maes E., Schoofs L., Nemery B., et al. Proteome analysis of multiple compartments in a mouse model of chemical-induced asthma. J Proteome Res 2010, 9(11):5868-5876.
21. Louten J., Mattson J.D., Malinao M.C., Li Y., Emson C., Vega F., et al. Biomarkers of disease and treatment in murine and cynomolgus models of chronic asthma. Biomark Insights 2012, 7:87-104.
22. Wu J., Kobayashi M., Sousa E.A., Liu W., Cai J., Goldman S.J., et al. Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol Cell Proteomics 2005, 4(9):1251-1264.
23. Calvo F.Q., Fillet M., de Seny D., Meuwis M.A., Maree R., Crahay C., et al. Biomarker discovery in asthma-related inflammation and remodeling. Proteomics 2009, 9(8):2163-2170.
24. Calvo F.Q., Fillet M., Renaut J., Crahay C., Gueders M., Hacha J., et al. Potential therapeutic target discovery by 2D-DIGE proteomic analysis in mouse models of asthma. J Proteome Res 2011, 10(9):4291-4301.
25. Zhang S., Xu N., Nie J., Dong L., Li J., Tong J. Proteomic alteration in lung tissue of rats exposed to cigarette smoke. Toxicol Lett 2008, 178(3):191-196.
26. Xu N.Y., Zhang S.P., Dong L., Nie J.H., Tong J. Proteomic analysis of lung tissue of rats exposed to cigarette smoke and radon. J Toxicol Environ Health A 2009, 72(11-12):752-758.
27. Gray R.D., MacGregor G., Noble D., Imrie M., Dewar M., Boyd A.C., et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008, 178(5):444-452.
28. Merkel D., Rist W., Seither P., Weith A., Lenter M.C. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005, 5(11):2972-2980.
29. Steiling K., Kadar A.Y., Bergerat A., Flanigon J., Sridhar S., Shah V., et al. Comparison of proteomic and transcriptomic profiles in the bronchial airway epithelium of current and never smokers. PLoS One 2009, 4(4):e5043.
30. Pastor M.D., Nogal A., Molina-Pinelo S., Melendez R., Romero-Romero B., Mediano M.D., et al. Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. Int J Mol Sci 2013, 14(2):3440-3455.
31. Franciosi L., Govorukhina N., Fusetti F., Poolman B., Lodewijk M.E., Timens W., et al. Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study. Electrophoresis 2013, 34(18):2683-2694.
32. Hu R., Ouyang Q., Dai A., Tan S., Xiao Z., Tang C. Heat shock protein 27 and cyclophilin A associate with the pathogenesis of COPD. Respirology 2011, 16(6):983-993.
33. Lee E.J., In K.H., Kim J.H., Lee S.Y., Shin C., Shim J.J., et al. Proteomic analysis in lung tissue of smokers and COPD patients. Chest 2009, 135(2):344-352.
34. Verrills N.M., Irwin J.A., He X.Y., Wood L.G., Powell H., Simpson J.L., et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183(12):1633-1643.
35. Tewari A.K., Popova-Butler A., El-Mahdy M.A., Zweier J.L. Identification of differentially expressed proteins in blood plasma of control and cigarette smoke-exposed mice by 2-D DIGE/MS. Proteomics 2011, 11(10):2051-2062.
36. Zhao J., Yeong L.H., Wong W.S. Dexamethasone alters bronchoalveolar lavage fluid proteome in a mouse asthma model. Int Arch Allergy Immunol 2007, 142(3):219-229.
37. Hur G.Y., Choi G.S., Sheen S.S., Lee H.Y., Park H.J., Choi S.J., et al. Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate-induced occupational asthma. J Allergy Clin Immunol 2008, 122(4):774-780.
38. Sastre J., Sastre B., Fernandez-Nieto M., Perez-Camo I., Sanchez J.J., Del Pozo V. Serum ferritin and transferrin levels are not serologic markers of toluene diisocyanate-induced occupational asthma. J Allergy Clin Immunol 2010, 125(3):762-764.
39. Vogelmeier C., Baur X., Fruhmann G. Isocyanate-induced asthma: results of inhalation tests with TDI, MDI and methacholine. Int Arch Occup Environ Health 1991, 63(1):9-13.
40. Petrak J., Ivanek R., Toman O., Cmejla R., Cmejlova J., Vyoral D., et al. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008, 8(9):1744-1749.
41. Haenen S., Clynen E., De Vooght V., Schoofs L., Nemery B., Hoet P.H., et al. Proteome changes in auricular lymph nodes and serum after dermal sensitization to toluene diisocyanate in mice. Proteomics 2012, 12(23-24):3548-3558.
42. Houtman R., Krijgsveld J., Kool M., Romijn E.P., Redegeld F.A., Nijkamp F.P., et al. Lung proteome alterations in a mouse model for nonallergic asthma. Proteomics 2003, 3(10):2008-2018.
43. Roh G.S., Shin Y., Seo S.W., Yoon B.R., Yeo S., Park S.J., et al. Proteome analysis of differential protein expression allergen-induced asthmatic mice lung after dexamethasone treatment. Proteomics 2004, 4(11):3318-3327.
44. Candiano G., Bruschi M., Pedemonte N., Caci E., Liberatori S., Bini L., et al. Gelsolin secretion in interleukin-4-treated bronchial epithelia and in asthmatic airways. Am J Respir Crit Care Med 2005, 172(9):1090-1096.
45. Jeong H., Rhim T., Ahn M.H., Yoon P.O., Kim S.H., Chung I.Y., et al. Proteomic analysis of differently expressed proteins in a mouse model for allergic asthma. J Korean Med Sci 2005, 20(4):579-585.
46. Larsen K., Malmstrom J., Wildt M., Dahlqvist C., Hansson L., Marko-Varga G., et al. Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma. Respir Res 2006, 7:11.
47. Jeong H.C., Lee S.Y., Lee E.J., Jung K.H., Kang E.H., Lee S.Y., et al. Proteomic analysis of peripheral T-lymphocytes in patients with asthma. Chest 2007, 132(2):489-496.
48. Ohlmeier S., Vuolanto M., Toljamo T., Vuopala K., Salmenkivi K., Myllarniemi M., et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res 2008, 7(12):5125-5132.
49. Rozanas C.R., Loyland S.M. Capabilities using 2-D DIGE in proteomics research: the new gold standard for 2-D gel electrophoresis. Methods Mol Biol 2008, 441:1-18.
50. Greenlee K.J., Corry D.B., Engler D.A., Matsunami R.K., Tessier P., Cook R.G., et al. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol 2006, 177(10):7312-7321.
51. Baggerman G., Vierstraete E., De Loof A., Schoofs L. Gel-based versus gel-free proteomics: a review. Comb Chem High Throughput Screen 2005, 8(8):669-677.
52. Gygi S.P., Corthals G.L., Zhang Y., Rochon Y., Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000, 97(17):9390-9395.
53. Pastor M.D., Nogal A., Molina-Pinelo S., Carnero A., Paz-Ares L. Proteomic biomarkers in lung cancer. Clin Transl Oncol 2013, 15(9):671-682.
54. Schweppe D.K., Rigas J.R., Gerber S.A. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 2013, 91:286-296.
55. Zhang W., Wei Y., Ignatchenko V., Li L., Sakashita S., Pham N.A., et al. Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches. Proteomics 2014, 14(6):795-803.
56. Alexandre B.M., Charro N., Blonder J., Lopes C., Azevedo P., Bugalho de Almeida A., et al. Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease. J Proteomics 2012, 76(Spec No.):259-269.
57. 18O stable isotope labeling in MS-based proteomics. Brief Funct Genomic Proteomic 2009, 8(2):136-144.
58. Bloemen K., Van Den Heuvel R., Govarts E., Hooyberghs J., Nelen V., Witters E., et al. A new approach to study exhaled proteins as potential biomarkers for asthma. Clin Exp Allergy 2011, 41(3):346-356.
59. Gharib S.A., Nguyen E.V., Lai Y., Plampin J.D., Goodlett D.R., Hallstrand T.S. Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol 2011, 128(6):1176-1184.
60. Zhao J., Zhu H., Wong C.H., Leung K.Y., Wong W.S. Increased lungkine and chitinase levels in allergic airway inflammation: a proteomics approach. Proteomics 2005, 5(11):2799-2807.
61. Liu H., Zhou L.F., Qian Z., Qian F.H., Yin K.S., Mao H., et al. Increased RhoGDI(2) and peroxiredoxin 5 levels in asthmatic murine model of beta(2)-adrenoceptor desensitization: a proteomics approach. Chin Med J 2008, 121(4):355-362.
62. Larsen K., Macleod D., Nihlberg K., Gurcan E., Bjermer L., Marko-Varga G., et al. Specific haptoglobin expression in bronchoalveolar lavage during differentiation of circulating fibroblast progenitor cells in mild asthma. J Proteome Res 2006, 5(6):1479-1483.
63. Bandow J.E., Baker J.D., Berth M., Painter C., Sepulveda O.J., Clark K.A., et al. Improved image analysis workflow for 2-D gels enables large-scale 2-D gel-based proteomics studies - COPD biomarker discovery study. Proteomics 2008, 8(15):3030-3041.
64. Bozinovski S., Hutchinson A., Thompson M., Macgregor L., Black J., Giannakis E., et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177(3):269-278.
65. Gomes-Alves P., Imrie M., Gray R.D., Nogueira P., Ciordia S., Pacheco P., et al. SELDI-TOF biomarker signatures for cystic fibrosis, asthma and chronic obstructive pulmonary disease. Clin Biochem 2010, 43(1-2):168-177.
66. Ohlmeier S., Mazur W., Linja-Aho A., Louhelainen N., Ronty M., Toljamo T., et al. Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. J Proteome Res 2012, 11(2):599-608.
67. Lee T.H., Jang A.S., Park J.S., Kim T.H., Choi Y.S., Shin H.R., et al. Elevation of S100 calcium binding protein A9 in sputum of neutrophilic inflammation in severe uncontrolled asthma. Ann Allergy Asthma Immunol 2013, 111(4):268-275.
68. Merali S., Barrero C.A., Bowler R.P., Chen D.E., Criner G., Braverman A., et al. Analysis of the plasma proteome in COPD: novel low abundance proteins reflect the severity of lung remodeling. COPD 2014, 11(2):177-189.
69. Tu C., Mammen M.J., Li J., Shen X., Jiang X., Hu Q., et al. Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients. J Proteome Res 2014, 13(2):627-639.
70. Irvin C.G. Using the mouse to model asthma: the cup is half full and then some. Clin Exp Allergy 2008, 38(5):701-703.
71. Waterston R.H., Lindblad-Toh K., Birney E., Rogers J., Abril J.F., Agarwal P., et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002, 420(6915):520-562.
72. Johnson V.J., Matheson J.M., Luster M.I. Animal models for diisocyanate asthma: answers for lingering questions. Cur Opinion Allergy Clin Immunol 2004, 4:105-110.
73. Wright J.L., Churg A. Animal models of COPD: barriers, successes, and challenges. Pulm Pharmacol Ther 2008, 21(5):696-698.
74. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172(5):2731-2738.
75. Kips J.C., Anderson G.P., Fredberg J.J., Herz U., Inman M.D., Jordana M., et al. Murine models of asthma. Eur Respir J 2003, 22(2):374-382.
76. Shapiro S.D. Animal models of asthma: Pro: allergic avoidance of animal (model[s]) is not an option. Am J Respir Crit Care Med 2006, 174(11):1171-1173.
77. Ware L.B. Modeling human lung disease in animals. Am J Physiol Lung Cell Mol Physiol 2008, 294(2):L149-L150.
78. Brusselle G.G., Bracke K.R., Maes T., D'hulst A.I., Moerloose K.B., Joos G.F., et al. Murine models of COPD. Pulm Pharmacol Ther 2006, 19(3):155-165.
79. De Vooght V., Vanoirbeek J.A., Luyts K., Haenen S., Nemery B., Hoet P.H. Choice of mouse strain influences the outcome in a mouse model of chemical-induced asthma. PLoS One 2010, 5(9):e12581.
80. Rueff-Barroso C.R., Trajano E.T., Alves J.N., Paiva R.O., Lanzetti M., Pires K.M., et al. Organ-related cigarette smoke-induced oxidative stress is strain-dependent. Med Sci Monit 2010, 16(7):BR218-BR226.
81. Vecchio D., Arezzini B., Pecorelli A., Valacchi G., Martorana P.A., Gardi C. Reactivity of mouse alveolar macrophages to cigarette smoke is strain dependent. Am J Physiol Lung Cell Mol Physiol 2010, 298(5):L704-L713.
82. Herrick C.A., Xu L., Wisnewski A.V., Das J., Redlich C.A., Bottomly K. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. J Allergy Clin Immunol 2002, 109(5):873-878.
83. Vanoirbeek J.A.J., Tarkowski M., Ceuppens J.L., Verbeken E.K., Nemery B., Hoet P.H.M. Respiratory response to toluene diisocyanate depends on prior frequency and concentration of dermal sensitization in mice. Toxicol Sci 2004, 80(2):310-321.
84. Matheson J.M., Johnson V.J., Vallyathan V., Luster M.I. Exposure and immunological determinants in a murine model for toluene diisocyanate (TDI) asthma. Toxicol Sci 2005, 84(1):88-98.
85. Tarkowski M., Vanoirbeek J.A., Vanhooren H.M., De Vooght V., Mercier C.M., Ceuppens J., et al. Immunological determinants of ventilatory changes induced in mice by dermal sensitization and respiratory challenge with toluene diisocyanate. Am J Physiol Lung Cell Mol Physiol 2007, 292(1):L207-L214.
86. De Vooght V., Vanoirbeek J.A., Haenen S., Verbeken E., Nemery B., Hoet P.H. Oropharyngeal aspiration: an alternative route for challenging in a mouse model of chemical-induced asthma. Toxicology 2009, 259(1-2):84-89.
87. Vanoirbeek J.A., Tarkowski M., De Vooght V., Nemery B., Hoet P.H. Immunological determinants in a mouse model of chemical-induced asthma after multiple exposures. Scand J Immunol 2009, 70(1):25-33.
88. Wenzel S., Holgate S.T. The mouse trap: it still yields few answers in asthma. Am J Respir Crit Care Med 2006, 174(11):1173-1176.
89. Zhang S.P., Xu N.Y., Nie J.H., Dong L., Li J.X., Tong J. Proteomic alteration in lung tissue of rats exposed to cigarette smoke. Toxicol Lett 2008, 178(3):191-196.
90. Zhang L., Wang M., Kang X., Boontheung P., Li N., Nel A.E., et al. Oxidative stress and asthma: proteome analysis of chitinase-like proteins and FIZZ1 in lung tissue and bronchoalveolar lavage fluid. J Proteome Res 2009, 8(4):1631-1638.
91. Noel-Georis I., Bernard A., Falmagne P., Wattiez R. Database of bronchoalveolar lavage fluid proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 771(1-2):221-236.
92. Magi B., Bargagli E., Bini L., Rottoli P. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 2006, 6(23):6354-6369.
93. Hu S., Loo J.A., Wong D.T. Human body fluid proteome analysis. Proteomics 2006, 6(23):6326-6353.
94. Ratjen F., Havers W., Braun J. Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia. Thorax 1999, 54(5):432-436.
95. Ray S., Reddy P.J., Jain R., Gollapalli K., Moiyadi A., Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11(11):2139-2161.
96. Blonder J., Issaq H.J., Veenstra T.D. Proteomic biomarker discovery: it's more than just mass spectrometry. Electrophoresis 2011, 32(13):1541-1548.
97. Schilsky R.L. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010, 9(5):363-366.
98. Clynen E., Baggerman G., Husson S.J., Landuyt B., Schoofs L. Peptidomics in drug research. Expert Opin Drug Discov 2008, 3(4):425-440.